MolecuLight

🌟 **Celebrating Healthcare Quality Week!** 🌟   This week, we recognize the importance of quality improvement in healthcare, and we're proud to highlight that MolecuLight is the only Class II Fluorescence Imaging Device on the market!   Being FDA Class II cleared signifies that MolecuLight meets stringent safety and efficacy standards, ensuring that healthcare professionals can trust our technology to accurately detect the presence and location of bacterial loads. This classification is founded in several FDA 510(k) clearances granted specifically to MolecuLight fluorescence imaging devices. We believe that validation of our technology to these high standards is critical to support the highest quality patient care.    As we celebrate #HealthcareQualityWeek, let’s continue to prioritize quality and innovation in our practices. Together, we can ensure better patient experiences and outcomes.   #HealthcareQualityWeek #MolecuLight #InnovationInHealthcare #PatientCare #FluorescenceImaging #FDAApproved

MolecuLight is the global leader in fluorescence imaging technology for real-time detection of harmful bacteria in wound care, provides the most effective method for bedside biofilm detection as reported in a groundbreaking study “Assessing Biofilm at the Bedside: Exploring Reliable Accessible Biofilm Detection Methods”. Published in Diagnostics Journal, this study is the first of its kind to compare various bedside methods for biofilm detection to enable immediate and effective therapeutic action.   #Biofilm is critically linked to various pathophysiological mechanisms that complicate or altogether prevent healing. Accurate #biofilm detection is often hindered by the need for specialized techniques, making it impractical for many clinical settings. This study compared promising bedside methods, including clinical signs of biofilm (CSB), biofilm blotting, and fluorescence imaging, against advanced gold standard laboratory-based methods. The results revealed a staggering incidence of biofilm in chronic wounds (62.5%), highlighting its critical relevance in influencing wound healing outcomes. Fluorescence imaging significantly improved the sensitivity and accuracy of biofilm detection over CSB and blotting, offering clinicians a more reliable biofilm detection tool. Read the full press release here: https://lnkd.in/grC-PknW Access the paper here: https://lnkd.in/gEpXzJAM

Dr David Armstrong remind us of the importance of an evidence based & objective diagnosis of bacterial presence, such as the obtained though MolecuLight , in the diabetic foot ulcer. Confirming the presence of infection, biofilm, or bacterial load in a diabetic foot ulcer influences surgical decisions by determining the need for debridement, the extent of tissue removal required, and whether more invasive procedures, like amputations, are necessary to prevent further complications. Find out more about this point of care, non-invasive, bacterial detection device by visiting our website: www.moleculight.com #WoundCare #Wound #FightAgainstAmputation #DiabeticFoot #Diabetes #Surgery #DiagnosticTechnology #ImagingTechnology #Biofilm

Wonderful SAWC meeting in Vegas, catching up with old friends and partners. Exciting to share our first experiences with Moleculight alongside Anil Amlani and team. Moleculight delivers results in seconds, complementing Debrichem's one-minute process. Great tools for follow-up. 🌟 #SAWC #Moleculight #Debrichem #healthcareinnovation #debxmedical #wounds #biofilm #infection

Happy to participate in University Health Network ‘s UNHLeashed innitiative. A fantastic Commerzialization & Partnership Showcase. Our CEO Anil Amlani delivered a great presentation that highlighted MolecuLight ‘s value proposition and sparked lots of interest and discussion! #wounds #woundcare #biomarkers #valueproposition

We are excited to announce the publication of a new study that addresses a critical challenge in wound care: the need for standardized and evidence-based antibiotic and antimicrobial prescribing. Published in Diagnostics, this groundbreaking research underscores the urgent need for widespread adoption of antimicrobial stewardship programs (ASPs) and reveals the significant potential to improve prescribing practices with MolecuLight .   The study, led by Dr. Thomas Serena and titled “Audit of Antimicrobial Prescribing Trends in 1447 Outpatient Wound Assessments: Baseline Rates and Impact of Bacterial Fluorescence Imaging”, examined antimicrobial prescribing practices in 2022 across eight U.S. outpatient wound clinics. By comparing trends between clinics with and without MolecuLight, the research provides valuable insights into current prescribing practices and the impact of MolecuLight on antimicrobial use.   Dr. Serena, a dedicated advocate in the fight against #antimicrobialresistance, shares his insights: "Antimicrobial resistance is a critical challenge across all areas of medicine, including wound care. Our study represents a significant advancement in tackling this issue. We discovered that using fluorescence imaging during patient assessments reduced the average number of concurrent medications prescribed—from 1.4 per patient with standard clinical examination to just 1 per patient. Additionally, systemic antibiotics made up only 8% of prescriptions in the fluorescence group, compared to 36% in the standard care group."   He continues, "Our research highlights a notable shift towards topical prescriptions in the fluorescence imaging group (92%) compared to standard care (64%). These results emphasize the profound impact of real-time diagnostic technologies. In this case, MolecuLight enabled clinicians to make immediate and informed decisions, reducing the reliance on systemic antibiotics and reinforcing the efficacy of localized treatments, as supported by extensive research." Read the full press release here: https://lnkd.in/eEcPbd3Z Access the paper here: https://lnkd.in/gGf8VfPV

Its been wonderful connecting with clinicians at Symposium on Advanced Wound Care (SAWC) Fall 2024 in Las Vegas! The MolecuLight team will be at booth #431 between 12:30 - 2:00pm tomorrow, stop by! #woundcare #woundinfection #SAWC

MolecuLight’s showing at SAWC Fall spans a range of clinical applications and highlights new device features. These include optimized wound bed preparation ahead of skin grafting and cellular and tissue-based product (CTP) application, automatic digital wound depth measurement for streamlined workflow, thermal imaging to detect and better treat pressure injuries, associating fluorescence signals with diabetic ulcer healing, and other innovative approaches to wound care. The clinical posters featuring the MolecuLight at SAWC Fall 2024 are as follows: ·      Poster CR-001, “Imaging Beyond the Wound Bed: Leveraging Fluorescence Imaging of Non-Biologicals to Enhance Bacterial-Infection Management”, presented by Dr. Charles Andersen   ·      Poster CR-002, “The New Age of Wound Care: Leveraging the Synergy of Multi-modal Fluorescence and Thermal Imaging”, presented by Dr. Charles Andersen   ·      Poster CR-020, “Validation of a Digital Automatic-Depth Measurement Feature within a Multi-Modal Wound Imaging Device”, presented by Dr. Laura Jones   ·      Poster CR-029, “Bacterial fluorescence imaging improves chronic wound biofilm detection over standard clinical assessment and blotting”, presented by Dr. Laura Jones   ·      Poster CR-063, “Bacterial Fluorescence in the Application of Cellular Tissue Products”, presented by Dr. Alisha Oropallo   ·      Poster CR-064, “Co-localization of High Bacterial Load with Regions of Pain in Venous Leg Ulcers: Fluorescence Imaging Informs Interventions and Validates Patient Self-Reported Pain”, presented by Dr. Alisha Oropallo   ·      Poster CS-012, “Advancing Pyoderma Gangrenosum Wound Care Through Fluorescence-Guided Debridement”, presented by Dr. Charles Andersen   ·      Poster CS-115, “The Interface of Cutting-Edge Technology in Mission Sustained Injuries of U.S. Special Operations”, presented by Dr. Charles Andersen   ·      Poster CS-151, “The Association of Bacterial Autofluorescence Signals with Healing Outcomes in Diabetic Foot Ulcers”, presented by Dr. Stephanie Woelfel   ·      Poster CS-157, “Update on pressure ulcer diagnosis and management: Leveraging Fluorescence and Thermal Imaging”, presented by Dr. Charles Andersen In addition to the clinical posters at SAWC Fall 2024, the MolecuLight i:X® and DX™ imaging devices will be available for demonstration in the MolecuLight Booth #431 in the Exhibition Hall. Read the full press release here: https://lnkd.in/e9NuNhyY

Nearly 50% reduction in antibiotic use! The use of fluorescence imaging in antimicrobial stewardship.

MolecuLight ’s Industry Leading DX Measurement now with Automatic Depth Calculation   Capture all wound measurement data in a single shot:   - Streamline your workflow, save time, enhance accuracy. - Automatically measure wound depth without the need for stickers or manual input. - Effortlessly document tunneling and undermining. - Seamless data transfer to your EHR system.   Contact MolecuLight to see a live Demo of AutoDepth: https://lnkd.in/gksWM5RP Read the full press release here: https://lnkd.in/gRiwbwQ9   #woundcare #healthcare #medicaltechnology #healthcareinnovation #MolecuLight #AutoDepth #skinsubstitues #CAMPs #reconstructivesurgery #plasticsurgery